Overview of Intal 5

Quick Facts

Property	Description
Active ingredient	Sodium Cromoglycate (Cromolyn Sodium)
Form	Inhalation Aerosol (MDI) or Inhalation Solution
Pharmacological class	Mast Cell Stabilizer
General purpose	Prophylactic maintenance of the airways
Origin	Synthetic, derived from a chromone structure

What is the Active Ingredient and Pharmacological Class of Intal 5?

Intal 5 is a medicinal preparation whose active component is the single ingredient Sodium Cromoglycate (Cromolyn Sodium), and it is classified as a Mast Cell Stabilizer, falling under the category of non-steroidal, anti-allergic compounds. This substance is a synthetic derivative of the chromone khellin, possessing stability-enhancing properties. It is most often formulated as an Inhalation Aerosol (Metered Dose Inhaler or MDI) or an Inhalation Solution for nebulization, ensuring direct delivery of the white, crystalline powder to the respiratory tract.

The product Intal 5 is specifically designated as a metered-dose inhaler providing five milligrams per actuation, positioning it as a dedicated treatment option for patients requiring reliable, consistent dosing via the inhalation route.

Is Intal 5 Used to Prevent Symptoms or Treat Attacks?

The core general purpose of Intal 5 is prophylactic maintenance—it is used to help prevent the onset of symptoms, rather than providing immediate relief during an acute episode. Its function is to stabilize specific immune cells in the airways, known as mast cells, thereby inhibiting the release of chemical mediators like histamine and leukotrienes that trigger allergic inflammation. Clinically, this mechanism is recognized for its established use in preventing symptoms that might be triggered by factors such as physical exertion or exposure to known environmental allergens. The drug is utilized as a protective measure to keep airways less sensitive over time. Consequently, the full benefit of the drug is achieved through its regular, continuous administration, serving as a preventative measure for long-term airway sensitivity management.

What side effects are possible with Intal 5?

Possible Side Effects and Safety Information

The safety profile for inhaled Sodium Cromoglycate (Cromolyn Sodium) is formally defined by regulatory documents, which categorize adverse reactions by frequency and affected physiological system. The adverse events most frequently reported are generally local and transient, related primarily to the inhalation route of administration.

Frequency Classification of Adverse Reactions

Adverse reactions are classified according to frequency in regulatory labeling:

Common: Adverse events reported include a transient cough and mild wheezing, particularly when using the powder inhalation form, as noted in clinical experience [FDA Access Data].
Occasionally: Reactions such as headache, sneezing, and an unpleasant taste in the mouth have been reported with the nebulizer solution [Health Canada PM].
Rare Events: Serious systemic reactions are considered rare, generally occurring in less than 1 in 10,000 cases.

Systemic and Serious Reactions

The most commonly affected body system is the Respiratory, Thoracic and Mediastinal system, listing effects such as cough, wheezing, and bronchospasm. While uncommon, serious adverse reactions documented in official sources include manifestations of hypersensitivity and immunologic changes. These rare systemic events may involve anaphylaxis, severe bronchospasm, or complex conditions such as polymyositis, pneumonitis, or pulmonary infiltrates with eosinophilia [FDA Access Data, Health Canada PM].

Population-Specific Safety Notes

The medication is contraindicated in patients with documented hypersensitivity to sodium cromoglycate or any of its non-active components. Safety notes for specific populations require caution: dose selection for older adults should account for the increased frequency of decreased hepatic, renal, or cardiac function. Use during pregnancy is limited to instances of clear clinical need, consistent with a Pregnancy Category B classification [FDA Access Data]. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Overdose and Emergency Response

The official regulatory profile for an overdosage of Intal 5 (Sodium Cromoglycate) inhalation is defined by the substance's extremely low order of acute toxicity and the absence of a defined clinical syndrome in cases of overexposure. This information is consistently documented in prescribing information issued by government health authorities.

Classification	Official Regulatory Status
Severity Classification	Characterized by an extremely low order of toxicity and lack of severe outcomes.
Documented Manifestations	The official label explicitly states that no clinical syndrome has been associated with an overdosage.
Antidote Information	No specific antidote is described in the regulatory documentation.

Official Overdose Statements:

The regulatory labeling explicitly states that no clinical syndrome has been associated with an overdosage of inhaled Sodium Cromoglycate.
Acute toxicity testing, referenced in official documents, demonstrates an extremely low order of toxicity for this substance.
Management of overexposure is generally described as symptomatic and supportive treatment.
Regulatory guidance mandates that a person seek immediate medical attention or contact a poison control center upon known or suspected overexposure to the medication.

Connection to the overall overdose profile:

The regulatory documents establish that due to the lack of a specific toxic profile, overdosage is not associated with defined clinical symptoms or severe, life-threatening outcomes. Therefore, the required emergency action is the universal regulatory mandate to seek immediate medical attention upon any known or suspected overexposure, which ensures professional evaluation and supportive care.

Therapeutic Uses of Intal 5

What Intal 5 Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, and is commonly used for the prophylactic management of the airways. It is commonly used across conditions presenting with recurrent or episodic manifestations related to bronchial asthma. Specifically, it is considered relevant for managing conditions like mild to moderate asthma and the prevention of Exercise-Induced Bronchoconstriction (EIB).

This medication helps address symptom clusters that may become intense or disruptive, such as wheezing, shortness of breath, and chest tightness. It is applied in scenarios where additional management of discomfort is required before known triggers, like exposure to cold air or environmental allergens. This approach assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

“This supportive relief helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Support for Airway Reactivity

Symptom Category	Therapeutic Goal (Prophylaxis)
Recurrent Symptoms	Contributes to easing the overall symptom load during symptomatic periods.
Trigger-Induced Spasm	Provides supportive relief when symptoms interfere with routine activities like exercise.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Intal 5?

Regulatory documents define eligibility for Intal 5 (Cromolyn Sodium Inhalation) based on absolute exclusions, age thresholds, and specific conditional use requirements.

Contraindicated Populations

Category	Population Status
Hypersensitivity	Contraindicated in patients with a known allergy to cromolyn sodium or its excipients.
Acute Asthma	Contraindicated for use during an acute asthma attack or status asthmaticus, as it has no role as a rescue medicine.

Age and Conditional Use Restrictions

Category	Eligibility Rule
Children	Established use begins at age 5 for the inhaler (MDI) and age 2 for the nebulizer solution; safety and effectiveness are not established below these ages.
Organ Function	Use requires caution and consideration for dosage adjustment or discontinuation in patients with impaired renal or hepatic function.
Pregnancy	Use during pregnancy (Category B) is conditional and permitted only if clearly needed, due to the absence of adequate, controlled human studies.
Cardiac Status	The MDI formulation should be used with caution in patients with coronary artery disease or a history of cardiac arrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Intal 5 (Sodium Cromoglycate) inhalation is defined by the drug’s minimal potential for systemic interaction. Following inhalation, Sodium Cromoglycate is poorly absorbed into the bloodstream and is excreted rapidly and completely as the unchanged compound via the urine and bile. This pharmacokinetic profile leads to a formal regulatory determination of no known systemic drug–drug interactions (DDIs). Consequently, official government labeling does not list any specific medicinal products as posing a formal systemic pharmacokinetic or pharmacodynamic risk, and no combinations are formally classified as contraindicated based on systemic interaction effects. No interactions with food, alcohol, or supplements are documented for the inhalation route.

Administration and Clearance Constraints

Despite the low systemic interaction risk, official documents identify specific constraints related to administration and patient physiology:

Constraint Category	Official Regulatory Statement
Administration Compatibility	The Inhalation Solution must not be mixed with other medicines in the nebulizer device. This is a physical compatibility restriction established due to unverified safety and stability of co-mixtures within the delivery device.
Population-Specific Clearance	Consideration must be given to patients with impaired renal or hepatic function. The drug relies on both biliary and renal pathways for its clearance, meaning the possibility of altered clearance and potential systemic exposure change exists in these specific populations.

Mechanism of Action

How Intal 5 Works

Mast Cell Membrane Stabilization

This mechanism involves the compound's primary action: the inhibition of mast cell degranulation. Cromolyn sodium interacts with mast cells, thereby preventing the rapid release of pre-formed inflammatory mediators, including histamine and leukotrienes, which typically follows cell stimulation. This interaction maintains mast cell membrane integrity and limits the discharge of granular contents into surrounding tissue.

Modulation of Intracellular Signaling

The stabilization effect is achieved by interfering with necessary intracellular processes, specifically by modulating the influx of calcium ions ( Ca^2+) across the mast cell membrane. By suppressing this essential ionic signal, the compound modifies the molecular cascade required for mediator exocytosis. This results in altered signaling activity within the targeted immune pathways.

Attenuation of Inflammatory Cascade Phases

Cromolyn sodium's activity affects both the immediate-phase and the late-phase inflammatory reactions triggered by a challenge. By limiting both the initial burst of stored mediators and the subsequent synthesis, release, and cellular recruitment characteristic of the later phase, the compound modifies the inflammatory signaling profile, leading to attenuated downstream physiological consequences relative to the unmodulated cascade.

Dosage and Administration Information

Intal (Sodium Cromoglycate) is intended exclusively for prophylactic use and is administered via the oral inhalation route, defining its function as continuous maintenance therapy. The standard formulations include the Inhalation Aerosol (MDI), which may deliver 5 mg per metered dose, and the 20 mg Inhalation Solution for use with a power-driven nebulizer.

Official Usage Patterns

The usage protocol is based on a continuous daily schedule and time-specific pre-event dosing:

Maintenance Regimen: The common starting and maintenance pattern requires administration four times daily (QID) at regular intervals. The typical starting dosage is two metered inhalations QID for the MDI or the full contents of one 20 mg ampule QID for the nebulizer.
Acute Prevention: For anticipated exposure to triggers, a single dose must be administered 10 to 60 minutes prior to the event.

Procedural and Duration Constraints

Therapy relies on long-term administration; the full prophylactic effect may require two to four weeks of continuous use. Once control is established, the dose may be gradually reduced to the minimum effective level. If the drug is to be stopped, the dosage should be progressively tapered over one week. The medication is strictly prohibited for use during an acute episode of bronchospasm. When using concomitant inhaled medications, a bronchodilator should be administered prior to the Intal dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Intal 5

Evidence for Prophylactic Management of Mild to Moderate Asthma

Clinical research for this medication has been primarily conducted using Randomized Controlled Trials (RCTs) and subsequent systematic reviews, which are study designs used in research exploring how symptoms change over time. These trials were used in research examining the role of regular use of this medicine in the context of chronic asthma.

Research examined outcomes related to physical discomfort, such as daily symptoms of wheezing, cough, and shortness of breath, which were tracked using patient diaries. Studies also monitored objective measures, including lung function tests like FEV1 and PEFR. Findings describe patterns observed in the studies, where these outcomes were monitored during the study period. Studies reported how symptoms evolved in the observed populations, and the research monitored changes related to the requirement for additional rescue medications.

The core body of evidence that established the initial clinical evaluation of this medicine for asthma management dates from earlier scientific eras. Long-term outcomes and the durability of measured effects beyond the initial short-term trial periods are not fully established by more contemporary, extended duration data. Comparative evidence is lacking for direct comparison against newer, modern standard-of-care treatments for asthma, meaning results apply primarily to the populations and comparators studied in the original trials.

Evidence for Preventing Exercise-Induced Bronchoconstriction (EIB)

Research for this specific use was evaluated in specialized single-dose challenge studies and crossover trials. These studies focus on episodes where symptoms become more noticeable due to a specific trigger, such as exercise. The research explores short-term symptom changes, with the medication administered shortly before the activity.

Studies monitored objective outcomes reflecting physiological strain or stress, specifically measuring the maximum drop in lung function (like FEV1) immediately after a standardized exercise test. Research highlights measurements taken during the study period, with findings describing patterns in the post-exercise decline in lung function. This type of evidence contributes to understanding the patterns of episodic or acute changes following a known trigger.

Consistency and Gaps in the Research Evidence

The evidence base for Intal 5 is mature, meaning most of the foundational research is not recent. This results in certain research limitations frames where comparative evidence is lacking against modern treatments. The available data describe patterns related to symptom measurements and pre-exposure outcomes, but the evidence base is limited when considering the applicability of these findings to modern clinical practice settings without recent large-scale trials.

Findings describe group patterns, not personal outcomes, and research provides insight into short-term changes. Evidence quality varies across studies, and the interpretation must consider that the results apply only to the populations studied under the specific conditions of the original trials.

Key Studies & References

Cromolyn Sodium Inhalation Solution, USP PRESCRIBING INFORMATION

Frequently Asked Questions (FAQ)

Common questions about Intal 5 (FAQ)

Q: Is it possible to feel no effects after starting Intal 5?

According to official product information, this medication is designed for continuous prophylactic use, meaning it works to prevent symptoms over time. The full protective benefit of the drug may take up to two to four weeks of regular administration to be fully realized.

Q: What kind of medical professional usually prescribes Intal 5?

Intal 5 is only available with a prescription. It is to be administered as directed by a healthcare professional or physician, who determines the appropriateness of the medication.

Q: Are there any specific foods or drinks that should be avoided with Intal 5?

Official regulatory documents state that no interactions with specific foods, drinks, or alcohol have been formally documented for the inhalation form of this medication. This is due to its poor systemic absorption, which limits its potential for drug-food interactions.

Q: Can Intal 5 cause drowsiness or affect driving?

Drowsiness has been reported as an adverse reaction in clinical trials examining this medication. However, official regulatory documents indicate that a definitive causal relationship between Intal 5 and drowsiness was not formally established.

Q: What happens if a user forgets to use Intal 5 as directed?

If a regular dose is missed, regulatory patient information describes using it as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. The instructions indicate that extra medication should not be used to make up for a missed dose.

Q: Does Intal 5 have any specific warnings for older adults?

Official safety notes indicate that dose selection for older adults requires caution and careful consideration. This is because there is an increased likelihood of decreased hepatic (liver), renal (kidney), or cardiac (heart) function in this population, which could potentially alter the way the drug is processed by the body.

Q: Is Intal 5 addictive or habit-forming?

According to regulatory documentation in the United States, Sodium Cromoglycate, the active ingredient in Intal 5, is not classified as a controlled substance. This classification describes the drug's status regarding the potential for abuse or dependency.

Q: Can Intal 5 be taken alongside vitamins?

Official regulatory documentation states that no interactions with vitamins or other dietary supplements are formally documented for the inhalation form of this medication. This is because the drug is poorly absorbed into the bloodstream.

Q: Does Intal 5 lose its effectiveness over time?

The intended protective effect of this medication relies on its administration at regular, continuous intervals. Regulatory documents note that symptoms of the underlying condition may recur if the medication is reduced or stopped altogether.

Q: How long does the effect of Intal 5 typically last?

Intal 5 is a preventative medication intended for continuous use. The standard maintenance regimen requires administration four times daily (QID) at regular, set intervals. This schedule is designed to help maintain the drug's intended prophylactic (protective) effect in the airways.

Q: Is Intal 5 often combined with other medicines?

Official product information states that this medication may be used alone or in combination with other medicines for airway management, such as bronchodilators or inhaled corticosteroids. Regulatory instructions describe the administration of a bronchodilator prior to taking Intal 5 when the two are used together.

Q: Does Intal 5 come in different forms, like a tablet or liquid?

Intal (cromolyn sodium) is available in two forms for inhalation. These are the Inhalation Aerosol, which is dispensed via a metered-dose inhaler (MDI), and the Inhalation Solution, which is administered using a power-driven nebulizer.

Q: What is the risk level of Intal 5 according to regulatory bodies?

Regulatory documents classify the drug's safety profile by frequency of adverse reactions, stating that serious systemic reactions are considered rare events. The FDA determined that this medication was not withdrawn from the market for reasons related to safety or effectiveness, which reflects its formal regulatory status.

Q: Is it necessary to use Intal 5 with a specific device?

Yes, the method of administration requires specific devices for both available forms. The Inhalation Solution must be administered using a power-driven nebulizer. The Inhalation Aerosol requires its own specialized metered-dose inhaler (MDI) device.

Q: Can Intal 5 be purchased without a prescription?

The inhalation solution and aerosol forms of cromolyn sodium are classified as prescription-only medications by regulatory authorities. They cannot be purchased without a valid prescription from a licensed healthcare provider.

Q: Can Intal 5 be used for children or teens?

Official documents specify the age thresholds for use. The Inhalation Aerosol form is established for use in children aged 5 years and older. The Inhalation Solution form for nebulization is established for children aged 2 years and older.

Q: Does Intal 5 interact with over-the-counter pain relievers?

Regulatory documents formally classify the inhalation form of this medication as having no known systemic drug-drug interactions (DDIs). This is due to its poor absorption into the bloodstream, minimizing the risk of interaction with common oral medications, including pain relievers.

Q: Can Intal 5 interact with herbal supplements?

Official product information states that no formal interactions with herbal or other dietary supplements have been documented for this inhalation product. This determination is based on the drug’s pharmacokinetic profile, which shows minimal systemic absorption.

Q: What is the difference between Intal 5 and Intal 10?

Intal 5 and similar product designations refer to different dosage strengths of the same active ingredient, Sodium Cromoglycate. The number typically references the milligrams ( mg) of the active ingredient present in a single metered dose or unit.

Q: What are the most common reasons a doctor might choose Intal 5 over another option?

The established role of the medication is defined by regulatory documents for the management of bronchial asthma and for the prevention of symptoms caused by triggers, such as exercise. It is classified as a non-steroidal, prophylactic (preventative) agent.

Q: Are headaches a common concern for users of Intal 5?

Headache has been reported as an adverse reaction in clinical experience, specifically with the nebulizer solution form. Regulatory bodies classify this occurrence as occasional, meaning it is not among the most frequently reported side effects.

Q: Are there common user complaints about the taste or smell of Intal 5?

Official regulatory documents list an unpleasant or metallic taste in the mouth as a reported adverse reaction. This specific concern related to the administration of the drug is classified by regulatory bodies as occurring occasionally.

How should Intal 5 be stored and disposed of?

Storage and Disposal Instructions for Intal 5 (Cromolyn Sodium)

The storage of Intal (cromolyn sodium) must strictly adhere to the conditions mandated by regulatory labeling to maintain product stability.

Storage Requirements

The product must be stored at Controlled Room Temperature, typically defined as 15 C to 30 C (59 F to 86 F). It is strictly prohibited to refrigerate or freeze this medicine. Intal must also be kept out of the sight and reach of children.

Condition	Requirement
Temperature	Store between 15 C and 30 C.
Protection	Protect from light, heat, and moisture.
Canister Integrity	Do not puncture, incinerate, or expose to high heat.

Disposal Requirements

Disposal must follow local regulations for pressurized waste. The inhaler canister should not be placed in household trash, but rather returned to a pharmacist or an approved local collection program. The canister must also be discarded after the labeled number of actuations has been used.

Intal 5